Mark Bach
Chief Tech/Sci/R&D Officer presso STRUCTURE THERAPEUTICS INC.
Patrimonio netto: 61 712 $ in data 31/03/2024
Profilo
Il dott. Mark A. Bach, MD, è vicepresidente senior dello sviluppo clinico presso Ascendis Pharma A/S. Il Dr. Bach è stato precedentemente impiegato come amministratore delegato di Accumulus Synergy, Inc, Head-Asia Pacific Medical Sciences di Janssen Pharmaceuticals, Inc, Vice President-Research & Development di Janssen Pharmaceutical KK, e VP-Clinical Research Operations Worldwide di Merck & Co. Si è laureato al Carleton College, ha conseguito un dottorato all'Università di Chicago e un dottorato al Baylor College of Medicine.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 15/03/2024 | 4 320 ( 0.00% ) | 61 712 $ | 31/03/2024 |
Posizioni attive di Mark Bach
| Società | Posizione | Inizio |
|---|---|---|
| STRUCTURE THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 01/06/2021 |
Precedenti posizioni note di Mark Bach
| Società | Posizione | Fine |
|---|---|---|
| Accumulus Synergy, Inc | Chief Executive Officer | 01/10/2020 |
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Corporate Officer/Principal | 01/08/2019 |
Janssen Pharmaceutical KK
 Janssen Pharmaceutical KK Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals KK develops, manufactures, and markets prescription pharmaceutical products. The company was founded in 1978 and is located in Tokyo, Japan. | Chief Tech/Sci/R&D Officer | 01/11/2012 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2010 |
| ASCENDIS PHARMA A/S | Chief Tech/Sci/R&D Officer | - |
Formazione di Mark Bach
| Carleton College | Undergraduate Degree |
| The University of Chicago | Doctorate Degree |
| Baylor College of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| ASCENDIS PHARMA A/S | Health Technology |
| STRUCTURE THERAPEUTICS INC. | Commercial Services |
| Aziende private | 3 |
|---|---|
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
Janssen Pharmaceutical KK
Janssen Pharmaceutical KK Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals KK develops, manufactures, and markets prescription pharmaceutical products. The company was founded in 1978 and is located in Tokyo, Japan. | Health Technology |
| Accumulus Synergy, Inc |
- Borsa valori
- Insiders
- Mark Bach
